CD19内含子2的保留导致CD19发生亚克隆移码突变的白血病对CART-19产生耐药性。 - Suppr

Retention of CD19 intron 2 contributes to CART-19 resistance in leukemias with subclonal frameshift mutations in CD19.

作者信息

Asnani Mukta, Hayer Katharina E, Naqvi Ammar S, Zheng Sisi, Yang Scarlett Y, Oldridge Derek, Ibrahim Fadia, Maragkakis Manolis, Gazzara Matthew R, Black Kathryn L, Bagashev Asen, Taylor Deanne, Mourelatos Zissimos, Grupp Stephan A, Barrett David, Maris John M, Sotillo Elena, Barash Yoseph, Thomas-Tikhonenko Andrei

机构信息

Division of Cancer Pathobiology, Children's Hospital of Philadelphia, Philadelphia, PA, 19104, USA.

DBHi Bioinformatics Group, Children's Hospital of Philadelphia, Philadelphia, PA, 19104, USA.

出版信息

Leukemia. 2020 Apr;34(4):1202-1207. doi: 10.1038/s41375-019-0580-z. Epub 2019 Oct 7.

DOI:10.1038/s41375-019-0580-z

PMID:31591467

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7214268/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/64dd/7214268/7e1f30e31ef4/41375_2019_580_Fig1_HTML.jpg

相似文献

Retention of CD19 intron 2 contributes to CART-19 resistance in leukemias with subclonal frameshift mutations in CD19.

Leukemia. 2020 Apr;34(4):1202-1207. doi: 10.1038/s41375-019-0580-z. Epub 2019 Oct 7.

A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines.

J Immunother Cancer. 2017 May 16;5:42. doi: 10.1186/s40425-017-0246-1. eCollection 2017.

Chimeric Antigen Receptors: A Cell and Gene Therapy Perspective.

Mol Ther. 2017 May 3;25(5):1117-1124. doi: 10.1016/j.ymthe.2017.03.034. Epub 2017 Apr 26.

Improved anti-leukemia activities of adoptively transferred T cells expressing bispecific T-cell engager in mice.

Blood Cancer J. 2016 Jun 3;6(6):e430. doi: 10.1038/bcj.2016.38.

Generation of CD19-chimeric antigen receptor modified CD8+ T cells derived from virus-specific central memory T cells.

Blood. 2012 Jan 5;119(1):72-82. doi: 10.1182/blood-2011-07-366419. Epub 2011 Oct 26.

CD19 Isoforms Enabling Resistance to CART-19 Immunotherapy Are Expressed in B-ALL Patients at Initial Diagnosis.

J Immunother. 2017 Jun;40(5):187-195. doi: 10.1097/CJI.0000000000000169.

Genetic Mechanism of Leukemia Relapse Following CD19 Chimeric Antigen Receptor T Cell Therapy.

Cancer Biother Radiopharm. 2022 Jun;37(5):335-341. doi: 10.1089/cbr.2020.4630. Epub 2021 Mar 18.

A novel CD19-directed recombinant bispecific antibody derivative with enhanced immune effector functions for human leukemic cells.

J Immunother. 2008 Nov-Dec;31(9):871-84. doi: 10.1097/CJI.0b013e318186c8b4.

Sleeping Beauty transposon-mediated engineering of human primary T cells for therapy of CD19+ lymphoid malignancies.

Mol Ther. 2008 Mar;16(3):580-9. doi: 10.1038/sj.mt.6300404. Epub 2008 Jan 29.

Novel cellular therapies for leukemia: CAR-modified T cells targeted to the CD19 antigen.

Hematology Am Soc Hematol Educ Program. 2012;2012:143-51. doi: 10.1182/asheducation-2012.1.143.

引用本文的文献

Atypical lymphoid proliferations associated with therapeutic intervention: a report of the 2024 EA4HP/SH lymphoma workshop.

Virchows Arch. 2025 Aug 13. doi: 10.1007/s00428-025-04197-0.

FcRL1, a New B-Cell-Activating Co-Receptor.

Int J Mol Sci. 2025 Jun 30;26(13):6306. doi: 10.3390/ijms26136306.

IKAROS levels are associated with antigen escape in CD19- and CD22-targeted therapies for B-cell malignancies.

Nat Commun. 2025 Apr 23;16(1):3800. doi: 10.1038/s41467-025-58868-2.

Immunotherapy in chronic lymphocytic leukemia: advances and challenges.

Exp Hematol Oncol. 2025 Apr 10;14(1):53. doi: 10.1186/s40164-025-00644-5.

The costimulatory domain influences CD19 CAR-T cell resistance development in B-cell malignancies.

bioRxiv. 2025 Mar 4:2025.02.28.640707. doi: 10.1101/2025.02.28.640707.

The rewired immune microenvironment in leukemia.

Nat Immunol. 2025 Mar;26(3):351-365. doi: 10.1038/s41590-025-02096-9. Epub 2025 Feb 28.

Revolutionizing CAR T-Cell Therapies: Innovations in Genetic Engineering and Manufacturing to Enhance Efficacy and Accessibility.

Int J Mol Sci. 2024 Sep 26;25(19):10365. doi: 10.3390/ijms251910365.

Steering research on mRNA splicing in cancer towards clinical translation.

Nat Rev Cancer. 2024 Dec;24(12):887-905. doi: 10.1038/s41568-024-00750-2. Epub 2024 Oct 9.

A bibliometric and knowledge-map study on the treatment of hematological malignancies with CAR-T cells from 2012 to 2023.

Hum Vaccin Immunother. 2024 Dec 31;20(1):2371664. doi: 10.1080/21645515.2024.2371664. Epub 2024 Jul 3.

Expression of VISTA regulated via IFN-γ governs endogenous T-cell function and exhibits correlation with the efficacy of CD19 CAR-T cell treated B-malignant mice.

J Immunother Cancer. 2024 Jun 25;12(6):e008364. doi: 10.1136/jitc-2023-008364.

本文引用的文献

A large-scale binding and functional map of human RNA-binding proteins.

Nature. 2020 Jul;583(7818):711-719. doi: 10.1038/s41586-020-2077-3. Epub 2020 Jul 29.

Full-length transcript characterization of SF3B1 mutation in chronic lymphocytic leukemia reveals downregulation of retained introns.

Nat Commun. 2020 Mar 18;11(1):1438. doi: 10.1038/s41467-020-15171-6.

Alternative mRNA splicing in cancer immunotherapy.

Nat Rev Immunol. 2019 Nov;19(11):675-687. doi: 10.1038/s41577-019-0195-7. Epub 2019 Jul 30.

Escape From ALL-CARTaz: Leukemia Immunoediting in the Age of Chimeric Antigen Receptors.

Cancer J. 2019 May/Jun;25(3):217-222. doi: 10.1097/PPO.0000000000000381.

Aberrant splicing in B-cell acute lymphoblastic leukemia.

Nucleic Acids Res. 2018 Nov 30;46(21):11357-11369. doi: 10.1093/nar/gky946.

Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia.

Nat Med. 2018 Oct;24(10):1504-1506. doi: 10.1038/s41591-018-0146-z. Epub 2018 Oct 1.

CD19 Alterations Emerging after CD19-Directed Immunotherapy Cause Retention of the Misfolded Protein in the Endoplasmic Reticulum.

Mol Cell Biol. 2018 Oct 15;38(21). doi: 10.1128/MCB.00383-18. Print 2018 Nov 1.

Chimeric Antigen Receptor Therapy.

N Engl J Med. 2018 Jul 5;379(1):64-73. doi: 10.1056/NEJMra1706169.

SUPPA2: fast, accurate, and uncertainty-aware differential splicing analysis across multiple conditions.

Genome Biol. 2018 Mar 23;19(1):40. doi: 10.1186/s13059-018-1417-1.

Highly parallel direct RNA sequencing on an array of nanopores.

Nat Methods. 2018 Mar;15(3):201-206. doi: 10.1038/nmeth.4577. Epub 2018 Jan 15.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Retention of CD19 intron 2 contributes to CART-19 resistance in leukemias with subclonal frameshift mutations in CD19.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献